PMID- 37526141
OWN - NLM
STAT- MEDLINE
DCOM- 20231103
LR  - 20231108
IS  - 1555-3892 (Electronic)
IS  - 0963-6897 (Print)
IS  - 0963-6897 (Linking)
VI  - 32
DP  - 2023 Jan-Dec
TI  - HLA-B Matching Prolongs Allograft Survival in Islet Cell Transplantation.
PG  - 9636897231166529
LID - 10.1177/09636897231166529 [doi]
LID - 09636897231166529
AB  - Islet cell transplantation (ITx) is an effective therapeutic approach for 
      selected patients with type 1 diabetes with hypoglycemia unawareness and severe 
      hypoglycemia events. In organ transplantation, human leukocyte antigen (HLA) 
      mismatching between donor and recipient negatively impacts transplant outcomes. 
      We aimed to determine whether HLA matching has an impact on islet allograft 
      survival. Forty-eight patients were followed up after islet transplantation at 
      our institution from 2000 to 2020 in a retrospective cohort. Patients underwent 
      intrahepatic ITx or laparoscopic omental approach. Immunosuppression was 
      dependent upon the protocol. We analyzed HLA data restricted to A, B, and DR loci 
      on allograft survival using survival and subsequent multivariable analyses. 
      Patients were aged 42.8 +/- 8.4 years, and 64.3% were female. Diabetes duration was 
      28.6 +/- 11.6 years. Patients matching all three HLA loci presented longer graft 
      survival (P = 0.030). Patients with >/=1 HLA-B matching had longer graft survival 
      compared with zero matching (P = 0.025). The number of HLA-B matching was 
      positively associated with time of graft survival (Spearman's rho = 0.590; P = 
      0.034). Analyses adjusted for confounders showed that >/=1 matching for HLA-B 
      decreased the risk of allograft failure (P = 0.009). Our data suggest that HLA-B 
      matching between recipients and donors improved islet allograft survival. 
      Matching all three HLA loci (A, B, and DR) was also associated with prolonged 
      islet allograft survival. Prospective studies and a larger sample size are 
      warranted to validate our findings.
FAU - Lemos, Joana R N
AU  - Lemos JRN
AD  - Diabetes Research Institute (DRI) and Clinical Cell Transplant Program, Miller 
      School of Medicine, University of Miami, Miami, FL, USA.
FAU - Baidal, David A
AU  - Baidal DA
AD  - Diabetes Research Institute (DRI) and Clinical Cell Transplant Program, Miller 
      School of Medicine, University of Miami, Miami, FL, USA.
FAU - Poggioli, Raffaella
AU  - Poggioli R
AD  - Diabetes Research Institute (DRI) and Clinical Cell Transplant Program, Miller 
      School of Medicine, University of Miami, Miami, FL, USA.
FAU - Fuenmayor, Virginia
AU  - Fuenmayor V
AD  - Diabetes Research Institute (DRI) and Clinical Cell Transplant Program, Miller 
      School of Medicine, University of Miami, Miami, FL, USA.
FAU - Chavez, Carmen
AU  - Chavez C
AD  - Diabetes Research Institute (DRI) and Clinical Cell Transplant Program, Miller 
      School of Medicine, University of Miami, Miami, FL, USA.
FAU - Alvarez, Ana
AU  - Alvarez A
AD  - Diabetes Research Institute (DRI) and Clinical Cell Transplant Program, Miller 
      School of Medicine, University of Miami, Miami, FL, USA.
FAU - Ricordi, Camillo
AU  - Ricordi C
AD  - Diabetes Research Institute (DRI) and Clinical Cell Transplant Program, Miller 
      School of Medicine, University of Miami, Miami, FL, USA.
AD  - Division of Cellular Transplantation, Department of Surgery, Miller School of 
      Medicine, University of Miami, Miami, FL, USA.
FAU - Alejandro, Rodolfo
AU  - Alejandro R
AUID- ORCID: 0000-0003-4387-5360
AD  - Diabetes Research Institute (DRI) and Clinical Cell Transplant Program, Miller 
      School of Medicine, University of Miami, Miami, FL, USA.
LA  - eng
GR  - R01 DK025802/DK/NIDDK NIH HHS/United States
GR  - U42 RR016603/RR/NCRR NIH HHS/United States
GR  - M01 RR016587/RR/NCRR NIH HHS/United States
GR  - U01 DK070460/DK/NIDDK NIH HHS/United States
GR  - R01 DK055347/DK/NIDDK NIH HHS/United States
GR  - UL1 TR000460/TR/NCATS NIH HHS/United States
GR  - R01 DK056953/DK/NIDDK NIH HHS/United States
PT  - Journal Article
PT  - Research Support, N.I.H., Extramural
PT  - Research Support, Non-U.S. Gov't
PL  - United States
TA  - Cell Transplant
JT  - Cell transplantation
JID - 9208854
RN  - 0 (HLA Antigens)
RN  - 0 (HLA-B Antigens)
SB  - IM
MH  - Female
MH  - Humans
MH  - Male
MH  - Allografts
MH  - Graft Rejection
MH  - Graft Survival
MH  - Histocompatibility Testing/methods
MH  - HLA Antigens
MH  - HLA-B Antigens/genetics/analysis
MH  - *Hypoglycemia
MH  - *Islets of Langerhans Transplantation
MH  - Prospective Studies
MH  - Retrospective Studies
MH  - Adult
MH  - Middle Aged
PMC - PMC10395153
OTO - NOTNLM
OT  - human leukocyte antigens
OT  - islet survival
OT  - islet transplantation
OT  - type 1 diabetes
COIS- The author(s) declared no potential conflicts of interest with respect to the 
      research, authorship, and/or publication of this article.
EDAT- 2023/08/01 13:08
MHDA- 2023/08/01 13:09
PMCR- 2023/08/01
CRDT- 2023/08/01 06:35
PHST- 2023/08/01 13:09 [medline]
PHST- 2023/08/01 13:08 [pubmed]
PHST- 2023/08/01 06:35 [entrez]
PHST- 2023/08/01 00:00 [pmc-release]
AID - 10.1177_09636897231166529 [pii]
AID - 10.1177/09636897231166529 [doi]
PST - ppublish
SO  - Cell Transplant. 2023 Jan-Dec;32:9636897231166529. doi: 
      10.1177/09636897231166529.